In high-shear granulation trains for oral tablet manufacturing, pyrogallol pharma grade API is typically incorporated at 5–20% w/w of the core tablet mass when the finished dose requires an immediate-release matrix. Aqueous binder systems are not automatic first choices because pyrogallol undergoes base-catalysed autoxidation; the granulation fluid is buffered to pH 3.2–4.2 with citric acid monohydrate and purged with nitrogen to hold dissolved oxygen below 0.5 mg/L. A high-shear granulator fitted with a 150–350 rpm main impeller and 1,500–3,000 rpm chopper is charged with pyrogallol, microcrystalline cellulose 30–50% w/w, lactose monohydrate 20–40% w/w, and crospovidone 2–4% w/w. Binder solution containing hypromellose E5 at 3–5% w/w of the dry mass is sprayed under nitrogen overlay; wet massing is limited to 2–4 min because prolonged massing raises product temperature and accelerates chromophore formation. The wet mass is discharged at product temperature ≤40°C and dried in a fluid-bed dryer with inlet air at 50–60°C until loss-on-drying reaches 1.5–2.5% w/w. Dried granulate is milled through a 0.8–1.25 mm screen, blended with sodium stearyl fumarate 0.5–1.0% w/w as lubricant to avoid magnesium-associated discoloration, and compressed on a rotary tablet press with 10–20 kN compression force. Tablets are checked for hardness 60–90 N, friability <1.0% per USP <1216>, disintegration <15 min per USP <701>, and dissolution per USP <711> in 0.1 M HCl media at 37°C. Terminal product is a film-coated tablet packed in aluminium-aluminium blisters with molecular-sieve desiccant; oxygen scavenger sachets are added when the tablet core contains more than 10% w/w pyrogallol. Compliance follows FDA 21 CFR 211 for manufacturing quality, ICH Q3D for elemental impurities, and USP <467> for residual solvents. The main operational boundary is iron contamination; ferric ion at concentrations above 2 ppm forms dark pyrogallol-iron chelates, so product-contact surfaces are electropolished 316L stainless steel and cleaning validation includes post-rinse iron analysis. Ambient relative humidity above 60% requires pre-drying of excipients at 60°C for 2 h before weighing.

What Limits Pyrogallol Loading in Hard Gelatin Capsules?

Dry filling of hard gelatin capsules with pyrogallol is constrained less by chemical degradation during encapsulation than by the bulk powder properties of the API and the moisture sensitivity of the shell. Roller-compacted granulate is therefore preferred over direct blend filling. The dry granulation step combines pyrogallol 10–35% w/w, microcrystalline cellulose 40–60% w/w, lactose monohydrate 10–20% w/w, sodium starch glycolate 2–5% w/w, and colloidal silicon dioxide 0.5–1.0% w/w. The blend is preconditioned in a humidity-controlled suite at 40% RH or below. Roller compaction at 4–8 kN/cm linear force and granulation through a 0.8–1.25 mm screen produces free-flowing granulate with bulk density 0.55–0.70 g/mL; values outside this range cause weight variation on tamping-pin capsule machines. The granulate is lubricated with sodium stearyl fumarate 0.5–1.0% w/w and filled into size 0 or 1 hard gelatin capsules to a target fill weight of 250–500 mg. Machine speed is typically reduced to 60–80% of maximum because pyrogallol granulate can exhibit electrostatic adhesion at low humidity. Capsule shells are conditioned at 35–45% RH for 24–48 h before filling; gelatin shells stored above 50% RH soften and the enclosed pyrogallol granulate then forms tacky oxidation films on the inner wall. In-process controls include fill weight variation <±5%, dissolution per USP <711> in 0.1 M HCl at 50 rpm paddle speed, and content uniformity per USP <905>. Terminal product is a hard gelatin capsule packed in high-barrier PVC/PVDC or alu-alu blister with desiccant. Published data for specific pyrogallol capsule formulations is limited; therefore each blend must be characterised for Carr index and Hausner ratio before setting encapsulation speed. Humidity exceedance above 45% RH for more than 4 h during compaction is a batch rejection risk because the resulting granulate hardens and dissolution slows by more than 10 minutes.

When pyrogallol is distributed as oral granules for reconstitution or sachet dosing, the process window is dominated by residual moisture and headspace oxygen in the finished unit-dose package. A fluid-bed granulator is charged with pyrogallol 5–10% w/w, mannitol 60–80% w/w, microcrystalline cellulose 5–10% w/w, and hydroxypropyl cellulose 2–5% w/w. The binder is a hydroalcoholic solution of povidone K30 at 2–5% w/w in 70–90 vol% ethanol; the alcohol fraction reduces water contact time and shortens the drying cycle. Top-spray granulation runs at inlet air 40–55°C, product temperature 30–38°C, and spray rate 5–15 g/min per kg of bed load. Granules are dried to residual moisture <1.5% w/w and sieved to 250–850 µm; fines below 250 µm are re-granulated to avoid segregation in stick-pack filling. The terminal product is filled under nitrogen to headspace oxygen <3% v/v in aluminium foil stick packs or high-barrier sachets. Reconstitution requires an acidified vehicle at pH 3.5–4.5 because neutral or alkaline tap water produces immediate browning and turbidity. Compliance testing includes sieve distribution per Ph. Eur. 2.9.12, residual ethanol per USP <467>, and water content per Ph. Eur. 2.5.12. A formulation-dependent compatibility risk is the use of sulfite antioxidants; sodium metabisulfite at 0.1–0.25% w/w may form adducts with pyrogallol and should not be introduced without forced-degradation data. Equipment cleaning uses acidified water followed by nitrogen drying because alkaline detergents leave a coloured residue on stainless steel contact surfaces.

When Terminal Sterilization Replaces Aseptic Filtration for Pyrogallol Injection

Pyrogallol injection is normally filtered through a 0.22 µm PVDF membrane and filled aseptically because the trihydroxybenzene ring is thermally labile in aqueous media at neutral-to-alkaline pH. Terminal sterilization is viable only when the solution is maintained at pH 3.5–4.5 and dissolved oxygen is suppressed before autoclaving. Bulk solution is prepared in a 316L stainless steel vessel under pharmaceutical-grade nitrogen at 0.2–0.5 bar overpressure. The vehicle is Water for Injections containing sodium chloride 0.9% w/v for osmolality 280–320 mOsm/kg. Pyrogallol is added at 1–10 mg/mL; higher concentrations are avoided because autoxidation products exceed the colour threshold for injectable solutions. The solution pH is adjusted with dilute hydrochloric acid, and the tank is sparged with filtered nitrogen until dissolved oxygen remains below 0.5 mg/L. Sterile filtration proceeds through a 0.22 µm PVDF capsule at differential pressure <1.5 bar. If terminal sterilization is required, the filled ampoules or vials are autoclaved at 121°C for 15 min, corresponding to F0 ≥8 min; each cycle is qualified by thermocouple penetration and biological indicators per Ph. Eur. 5.1.1. The main degradation pathway is oxidative coupling to coloured purpurogallin-type products; measurable browning occurs after 30 min at 121°C when headspace oxygen exceeds 1.0% v/v. Amber glass vials or ampoules are used, and the filled container is blanketed with nitrogen to headspace oxygen <1.0% v/v. Terminal product is a clear injectable solution with visual inspection per USP <790> and particulate matter per USP <788>. Container closure integrity is verified per USP <1207>. The operational boundary is narrow; terminal sterilization of pyrogallol injection at pH above 5.0 produces unacceptable colour and assay loss, so pH specification is a batch release criterion, not a process-only target. Published data on terminal sterilization of pyrogallol injection is limited, and cycle-specific degradation profiles must be generated for each fill volume and headspace configuration.

Lyophilized Injectable: Stopper Moisture and Headspace Oxygen Control

Lyophilization isolates pyrogallol from water and reduces hydrolytic oxidation, but the finished cake remains highly hygroscopic and oxygen-labile. The bulk solution contains pyrogallol at 5–25 mg/mL and mannitol as a crystalline bulking agent at 5% w/v; trehalose is substituted for amorphous stabilization at a 1:1 to 1:2 pyrogallol-to-trehalose mass ratio when collapse temperature data require a non-crystalline matrix. The solution is filtered through 0.22 µm PVDF and filled into amber tubular glass vials under nitrogen. Freezing is conducted at -45°C for 4 h. Primary drying runs at shelf temperature -20°C and chamber pressure 100–150 µbar for 24–36 h; product temperature is monitored by thermocouples and kept below the collapse temperature. Secondary drying is performed at 25°C for 6–10 h until residual moisture by Karl Fischer volumetric titration is <1.0% w/w. Stoppers are pre-dried to internal moisture <0.1% w/w by dry heat; stopper moisture above 0.3% w/w transfers water to the cake during storage and should be rejected. Vials are stoppered under reduced pressure with nitrogen backfill to headspace oxygen <1.0% v/v. Terminal product is a white to off-white lyophilized cake that reconstitutes in <2 min with Water for Injections. Quality tests include cake appearance, reconstitution time, pH, assay, related substances, particulate matter per USP <788>, container closure integrity per USP <1207>, and stability under ICH Q1A(R2) conditions. The main operational boundary is moisture ingress through the stopper; butyl rubber formulations with water vapour transmission rate <0.05 g/m²/day at 40°C/75% RH are preferred. Nitrogen blanketing must be maintained during vial opening and stopper sorting, because the lyophilized cake absorbs atmospheric oxygen and develops a brown surface layer within 24 h at ambient conditions.

Does Oral Liquid Compounding Require More Than Low-pH Vehicle Control?

For extemporaneous oral liquid preparation from pyrogallol pharma grade API or from granules, pH adjustment alone does not prevent oxidative darkening; the compounded liquid must also be dispensed in an oxygen-barrier container with a short beyond-use date. The vehicle is typically a citrate buffer at pH 3.5–4.5 with sodium chloride or sorbitol for osmolality. Pyrogallol is added at 1–10 mg/mL; the solution becomes visibly discoloured within 4–8 h if dissolved oxygen exceeds 2 mg/L or if the container headspace is not nitrogen-blanketed. Compounding equipment is limited to glass or 316L stainless steel; contact with copper and iron accelerates chromophore formation. The final oral liquid is packaged in amber glass bottles with nitrogen headspace and stored at 2–8°C; a beyond-use date of 24 h is applied unless forced-degradation data support longer storage. Stability testing follows ICH Q1A(R2) stress conditions only where the product is intended for multidose clinical trial use. The critical in-use risk is patient access to ambient air after opening; therefore unit-dose amber glass vials are used rather than multidose bottles when the pyrogallol concentration exceeds 5 mg/mL. Published data for pyrogallol oral liquids in clinical practice is limited, and any compounded preparation should be verified by a stability-indicating HPLC method that resolves pyrogallol from purpurogallin degradation products.